Get started
Author

Tom Martin

Observed names: T Martin, T.G. Martin, Thomas G. Martin, Thomas Martin
OpenAlex ID: A5028954367
B04: Combination of Subcutaneous Teclistamab With Daratumumab in Patients With Relapsed/refractory Multiple Myeloma (rrmm): Results From a Phase 1b Multicohort Study
2022 · P Rodriguez-Otero, B Dholaria, et al. · HemaSphere · 7
Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma ( RRMM ): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis
2026 · Murali Janakiram, Carlyn R. Tan, et al. · American Journal of Hematology · 2
B06: Subcutaneous Talquetamab in Combination With Daratumumab in Patients With Relapsed/refractory Multiple Myeloma (rrmm): Phase 1b Results
2022 · M Mateos, P Hari, et al. · HemaSphere · 2
How long is long enough? Outcomes with finite-duration bispecific antibody therapy in multiple myeloma.
2026 · Eva Duvalyan, Jihong Song, et al. · Journal of Clinical Oncology · 1
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas
2026 · Efstathios Kastritis, Shaji K. Kumar, et al. · Journal of Clinical Oncology
PDF
Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone
2026 · Kwee Yong, Thomas Martin, et al. · Future Oncology
PDF
P44 | Earlier Use of Ciltacabtagene Autoleucel Is Associated With Better Immune Fitness and Stronger Immune Effects as Shown by Correlative Analysis of Peripheral Blood and the Bone Marrow Tumor Microenvironment From the Cartitude-4 Study
2026 · N.W.C.J. Van De Donk, S. Parekh, et al. · Haematologica
PDF
Works count: 8
Citation count: 12
H-index: 2
I10-index:
Year
Topic
Type